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at P. Incidence of grade III and IV neutropenia was 9% on D and none 
on P. Incidence of grade III and IV respiratory infection was 12% on D 
and 5% on P. Median OS was 17.94 months (95%CI: 14.82-21.06) for 
D and 18.92 months (95%CI: 13.24-24.61) for P (p=0.849). Median 
TTP from 1st line was 7.36 months (95%CI: 6.46-8.26) for D and 5.55 
months (95%CI: 4.43-6.67) for P (p=0.080). Median TTP from 2nd line 
was 3.75 months (95%CI: 1.98-5.52) for D and 3.18 months (95%CI: 
0.44-5.94) for P (p= 0.520).
Conclusions: As published, these results shows on our unselected 
daily practice population with NSCLC, a similar TTP and OS using 
docetaxel or pemetrexed as 2nd line treatment, but this later drug op-
tion shows a clear more favourable safety proﬁle.
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Purpose: Gemcitabine (GEM) and Vinorelbine (VNR) have dem-
onstrated activity as a ﬁrst-line treatment in elderly patients with 
advanced non-small-cell lung cancer (NSCLC). We conducted a mul-
ticenter phase II trial to evaluate the efﬁcacy and toxicity of bi-weekly 
administration of gemcitabine plus vinorelbine in elderly patients with 
advanced NSCLC. 
Patients and methods: Forty-six chemotherapy-naive elderly (age: 70 
years or older) NSCLC patients were enrolled. Patients were eligible if 
they had histologically or cytologically conﬁrmed unresectable NSCLC 
with measurable and/or assessable disease. Patients received GEM 
(1000 mg/m2) and VNR (25 mg/m2) every 2 weeks. 
Results: The objective response rate of this treatment was 22.7% (95% 
Conﬁdence Interval (CI), 10.3-35.1%), median survival time was 310 
days, and median time to progression was 133 days. The one-year sur-
vival rate was 40.9% (95% CI, 26.3-55.4%), and most adverse events 
were mild. Only 3 (6.8%) patients needed to omit GEM because of 
grade 4 neutropenia or due to physician judgment. No patients suffered 
treatment-related death. 
Conclusions: Bi-weekly administration of gemcitabine plus vinorel-
bine in elderly patients was an effective, feasible and well-tolerated 
treatment schedule.
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Background: Docetaxel is active against chemotherapy-pretreated 
non-small-cell lung cancer (NSCLC). S-1 is a novel oral ﬂuoropyrimi-
dine, composed of tegafur, 5-chloro-2,4-dihydroxypyridine (dihydro-
pyrimidine dehydrogenase inhibitor), and potassium oxonate (orotate 
phosphoribosyl transferase inhibitor). It has been commercially avail-
able and used for NSCLC in Japan. We conducted this study to evaluate 
the efﬁcacy and safety of docetaxel combined with S-1 in NSCLC 
patients (pts) who were previously treated with one or more regimens.
Methods: Eligible pts were required to have histologically or cytologi-
cally conﬁrmed measurable or evaluable stage IIIB or IV NSCLC, age≥ 
20 years, one or more previous chemotherapy, a performance status 
(PS) 0-1, and adequate organ function and bone marrow reserve. In this 
study, pts received S-1 (80mg/m2 orally on days 1-14) and docetaxel 
(40mg/m2 IV on days 1). Treatment was repeated every 3 weeks.
Results: Between January 2005 and May 2006, 30 pts were enrolled on 
this study. 29 pts were eligible and evaluable. Median age was 67 (48-
79), male/female (23/6), PS 0/1 (9/20), stage IIIB/IV (7/22), and prior 
chemotherapy regimen 1/2/3 (23/4/2). 28 pts received a platinum-based 
chemotherapy. Response: PR=7(24%), SD=13, PD=7, NE=2. Median 
survival time was 10.2 months. Grade 3/4 toxicities (% of pts) were as 
follows: leukocytes 6/0 (20.6%), neutrophils 7/3 (34.4%), platelets 0/0, 
infection 0/1 (3.4%), fever 2/0 (6.9%), diarrhea 1/0 (3.4%), neurology 
0/1 (3.4%), and mucositis 1/0 (3.4%). There were no treatment-related 
deaths.
Conclusions: The combination of docetaxel and S-1 was effective with
acceptable toxicity in pts with previously treated NSCLC. These results 
warrant further investigations of this regimen a randomized controlled 
trial as a second-line treatment for NSCLC.
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Background: Primary and acquired resistance to chemotherapy have 
been primary determinants of poor outcome in pts with metastatic 
NSCLC. Our group has shown that non-cytotoxic dose of suramin 
(10-50 ?M) produces chemosensitization in multiple preclinical tumor 
models, including chemo-pretreated tumors. 
Methods: Platinum-pretreated pts with stage IIIB/IV NSCLC (no 
prior docetaxel or gemcitabine allowed, allowed prior suramin) were 
randomized to receive 3 cycles of docetaxel (75 mg/m2 IV over 1 h q 3 
wks) + suramin (Arm A) or gemcitabine (1250 mg/m2 IV over 30 min 
d 1 and 8 q 3 wks) + suramin (Arm B). Suramin was infused over 30 
min, 2.5 hr prior to the chemotherapy. Suramin dose was calculated us-
ing a previously established dosing nomogram: Dose in mg = FACTOR 
x (actual body surface area) 2. Factor was 125 for the ﬁrst dose, and, 
for subsequent doses, was adjusted based on the time elapsed since the 
previous dose. Pts received either Arm A or Arm B and, after radiologic 
evaluation at 9 weeks (3 cycles), pts showing objective response (CR/
PR) were continued on the same Arm until progressive disease (PD) at 
which time pts crossed over to the other Arm, whereas pts with stable 
or PD immediately crossed over to the other Arm. Radiologic evalua-
tion was repeated after 3 cycles of treatments.
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Results: A total of 18 pts were treated. All had prior platinum and 16 
pts had prior taxanes; 15 were platinum-refractory (i.e., progressed on 
treatment or within 3 months after treatment) and 14 were taxane-re-
fractory. The ﬁrst group of 12 pts were randomized; 6 each to Arm A 
and Arm B. Toxicity was mild to moderate. In Arm A (docetaxel 75 mg/
m2 + suramin), 3 pts had neutropenic fevers. Therefore, the docetaxel 
dose was reduced by 25%, and 6 additional pts were treated with 56 
mg/m2 docetaxel + suramin. No febrile neutropenia was observed at 
the lower docetaxel dose or for pts treated with gemcitabine + suramin. 
Among the 18 pts, 4 received only gemcitabine + suramin, and 14 
received docetaxel + suramin (with or without rotating to gemcitabine 
+ suramin). Pharmacokinetic analysis revealed that the plasma suramin 
concentrations were <50 μM in all of the treatments and were >10 μM 
in 87% of all treatments. The following table summarizes the response 
and survival data. The group that received docetaxel + suramin ap-
peared to have more favorable response and survival compared to the 
group that received only gemcitabine + suramin. 
Group (n)
%  
platinum- 
refractory
% 
taxane-
refractory
Median # 
of cycles Best response, %
PFS 
Months 
MST, 
Months 
(95% CI)
1 yr 
survival 
%
    PD ORR SD    
Sur + Gem 
only (4) 100 75 2.5 50.0 0.0383 50.0
3.2  
(1.9, 5.3)
4.1  
(2.0, 6.9)  
Sur + Doc (5) & 
Sur + Doc/Gem 
(9)
79 79 5 23.1 15.4 61.5 4.0  (2.4, 5.3)
11.8  
(5.4, 14.0) 50.0
Overall (18) 83 78 3.5 27.8 11.1 61.1 3.9  (2.4, 5.0)
9.1  
(4.1, 12.7) 38.9
Conclusions: Combinations of nontoxic suramin with docetaxel 
56 mg/m2 or gemcitabine 1250 mg/m2 is well tolerated. Suramin + 
docetaxel (56 mg/m2) may have activity in paclitaxel/platinum-pretreat-
ed/refractory NSCLC patients. Supported in part by NCI UOlCA76576 
and Sanoﬁ-Aventis.
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Background: Pulmonary pleomorphic carcinoma is a rare tumor of 
the lung which is believed to spread at an early stage and to have an 
aggressive clinical course. The efﬁcacy of chemotherapy for advanced 
pulmonary pleomorphic carcinoma has not been deﬁned. The objective 
of this study was to evaluate the efﬁcacy of palliative chemotherapy for 
pulmonary pleomorphic carcinoma.
Methods: Thirteen consecutive patients who received palliative 
chemotherapy for advanced pulmonary pleomorphic carcinoma were 
investigated. All 13 patients were treated using chemotherapy regimens 
known to be active for the treatment of advanced non-small cell lung 
cancer (NSCLC).
Results: Of 13 patients, Nine were male (78.8%) and four were female 
(21.2%), and median age was 59 years with a range of 50 to 77 years.
Eleven patients (85%) had progressive disease and two (15%) had 
stable disease after ﬁrst-line chemotherapy. No patient achieved an 
objective response (objective response rate, 0%; 95% conﬁdence inter-
val, 0-23%). Eight of thirteen patients were given second-line chemo-
therapy, and all had progressive disease after second-line chemotherapy 
(objective response rate, 0%; 95% CI, 0-32%). Median overall survival 
from the initiation of ﬁrst-line palliative chemotherapy was only 4 
months (range, 2-12) with a median follow up of 16 months.
Conclusion: Advanced pulmonary pleomorphic carcinoma showed 
poor response to chemotherapy regimens that provide active treatment 
for NSCLC. Novel treatment approaches are required for pulmonary 
pleomorphic carcinoma.
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Background: A weekly administration of paclitaxel has demonstrated 
a sustained efﬁcacy and more favorable toxicity proﬁle than a 3-
weekly administration. The present study was conducted to evaluate 
the efﬁcacy and safety of a combination regimen of weekly paclitaxel 
plus carboplatin in patients with advanced non small cell lung cancer 
(NSCLC). In addition, we examined 6 polymorphism of ERCC1, 
XPD and XRCC1 and whether these polymorphism have an effect on 
response and survival in advanced NSCLC patients who have received 
this regimen. 
Methods: Patients with previously untreated measurable advanced 
NSCLC received intravenous paclitaxel 90 mg/m2 on days 1 and 8 
plus carboplatin AUC 6 on day 1 based on a 3-week cycle. We used 
polymerase chain reaction-restriction fragment length polymor-
phism to evaluate genetic polymorphism of the ERCC1 (Asn118Asn, 
Asp312Asn), XPD (Asp312Aap, Lys751Gln) and XRCC1 (Arg194Trp, 
Arg280His, Arg399Gln). 
Results: From August 2005 to date, 32 patients were enrolled in this 
study. An overall response rate was 43.7%. The estimated median time 
to progression and median overall survival was 5.4 months and 11.3 
months, respectively. Grade 3 neutropenia occurred in 7 patients, grade 
4 neutropenia in 2 patients and febrile neutropenia was observed in 1 
patient. Non hematologic toxicities were mild. There were no treat-
ment-related deaths. There was no relationship between polymorphisms 
of DNA repair gene and response rate.
Conclusions: A weekly paclitaxel and carboplatin combination was 
found to be well-tolerated and effective in patients with advanced 
NSCLC. Final data, including relationship between polymorphisms of 
DNA repair gene and survival, will be presented at the meeting. 
